Title Page 1

# Gut microbiota impacts bone via *B.vulgatus*-valeric acid-related pathways

- Xu Lin <sup>2, 1, #</sup>, Hong-Mei Xiao <sup>3, #, \*</sup>, Hui-Min Liu <sup>3</sup>, Wan-Qiang Lv <sup>3</sup>, Jonathan 5
- Greenbaum <sup>1</sup>, Si-Jie Yuan <sup>2</sup>, Rui Gong <sup>2</sup>, Qiang Zhang <sup>1</sup>, Yuan-Cheng Chen <sup>2</sup>, Cheng 6
- Peng<sup>2</sup>, Xue-Juan Xu<sup>2</sup>, Dao-Yan Pan<sup>2</sup>, Zhi Chen<sup>2</sup>, Zhang-Fang Li<sup>2</sup>, Rou Zhou<sup>2</sup>, 7
- Xia-Fang Wang <sup>2</sup>, Jun-Min Lu <sup>2</sup>, Zeng-Xin Ao <sup>2</sup>, Yu-Qian Song <sup>2</sup>, Yin-Hua Zhang <sup>2</sup>, 8
- Kuan-Jui Su <sup>1</sup>, Xiang-He Meng <sup>1</sup>, Chang-Li Ge <sup>4</sup>, Feng-Ye Lv <sup>4</sup>, Xing-Ming Shi <sup>5</sup>, Qi
- Zhao <sup>6</sup>, Bo-Yi Guo <sup>7</sup>, Neng-Jun Yi <sup>7</sup>, Hui Shen <sup>1</sup>, Christopher J. Papasian <sup>8</sup>, Jie Shen <sup>2</sup>, 10
- 9,\*, Hong-Wen Deng 1,3,\* 11

2

3 4

12 13

- 1 Tulane Center for Bioinformatics and Genomics, School of Public Health and 14
- Tropical Medicine, Tulane University, New Orleans, LA 70112, USA 15
- 2 Department of Endocrinology and Metabolism, The Third Affiliated Hospital of 16
- Southern Medical University, Guangzhou 510630, China 17
- 3 Center of System Biology, Data Information and Reproductive Health, School of 18
- Basic Medical Science, Central South University, Changsha 410008, China 19
- 4 LC-Bio Technologies (Hangzhou) CO., LTD., Hangzhou 310018, China 20
- 5 Departments of Neuroscience & Regenerative Medicine and Orthopaedic Surgery, 21
- 22 Medical College of Georgia, Augusta University, Augusta, GA, USA
- 6 Department of Preventive Medicine, College of Medicine, University of Tennessee 23
- Health Science Center, Memphis, TN 38163, USA 24
- 7 Department of Biostatistics, University of Alabama at Birmingham, Alabama 35294, 25
- 26 **USA**

32

- 8 Department of Basic Medical Science, School of Medicine, University of 27
- Missouri-Kansas City, 2411 Holmes Street, Kansas City, MO 64108 28
- 9 Shunde Hospital of Southern Medical University (The First People's Hospital of 29
- Shunde), No.1 of Jiazi Road, Lunjiao, Shunde District, Foshan City, Guangdong 30
- 31 Province, China
- # These authors contributed equally to this work. Correspondence should be 33
- addressed to Hong-Wen Deng (hdeng2@tulane.edu), Jie Shen (shenjiedr@163.com) 34
- and Hong-Mei Xiao (hmxiao@csu.edu.cn). 35

## Abstract

1

Although gut microbiota influences osteoporosis risk, the individual species involved, 2 3 and underlying mechanisms, are unknown. We performed integrative analyses in a Chinese cohort with metagenomics/targeted metabolomics/whole-genome 4 5 sequencing. Bacteroides vulgatus was found negatively associated with bone mineral density (BMD), this association was validated in US Caucasians. Serum valeric acid 6 was positively associated with BMD, and B.vulgatus causally downregulated it. 7 Ovariectomized mice fed B.vulgatus had decreased bone formation and increased 8 9 bone resorption, lower BMD and poorer bone micro-structure. Valeric acid suppressed 10 NF-κB p65 protein production (pro-inflammatory), and enhanced IL-10 mRNA expression (anti-inflammatory), leading to suppressed maturation of osteoclast-like 11 12 cells, and enhanced maturation of osteoblasts in vitro. B.vulgatus and valeric acid represent promising targets for osteoporosis prevention/treatment. 13

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Osteoporosis (OP), mainly characterized by low bone mineral density (BMD), predisposes to osteoporotic fracture, and is most prevalent in postmenopausal women (termed postmenopausal osteoporosis (PMOP)). 4.9 million post-menopausal women in US had osteoporotic fractures between 2000 and 2011, with greater hospital costs than myocardial infarction, stroke, and breast cancer <sup>1,2</sup>. The pathogenic mechanisms for PMOP and OP remain unclear, and current intervention and treatment options are not satisfactory <sup>1,2</sup>. Human studies have focused on the potential impact of inherent (e.g., (epi-)genome, proteome, metabolome) transcriptome, and external (e.g., environmental, medical/medication/nutrition, lifestyle) risk factors for OP <sup>3</sup>. Recently, however, experimental animal models have identified strong associations between gut microbiota (GM) and bone <sup>4</sup>. For example, Sjogren et al. found that absence of GM in mice leads to increased bone mass that normalizes following GM colonization <sup>5</sup>. In humans, four studies suggested the potential importance of GM for bone health 6-9, however, these studies had small sample sizes and did not identify specific bacterial species and associated functional mechanisms. To identify specific significant gut bacterial species and their functional mechanisms on bone health, we performed a novel systematic integrative multi-omics analysis of the human genome, GM and targeted metabolome [serum short chain fatty acids (SCFAs)] in 517 peri- and post-menopausal Chinese women. We identified several

bacterial species SCFAs and functional pathways that significantly impacted BMD.

We validated the major results in US Caucasians and investigated causal roles of

individual bacterial species and SCFAs in regulating bone metabolism in vitro in cells

and in vivo in mice. Our work is the first to identify individual BMD-associated GM

species and particularly GM-derived functional metabolites in humans, and establish

specific pathogenic mechanisms by which GM influences OP risk. Our results lay a

foundation for potential prevention/intervention/treatment of OP through GM and

metabolome alteration.

2

3

4

5

6

7

8

9

10

## **Chinese study cohort characteristics**

517 peri-/post-menopausal Chinese women were randomly recruited from Guangzhou 11 12 City, China; 84% were post-menopausal and 16% peri-menopausal, based on years since menopause (YSM) <sup>10</sup>. Mean YSM and follicle stimulating hormone (FSH) levels 13 were 1.96 years and 76.24 mIU/mL, respectively (Table 1). Age (mean  $\pm$ 14 standard deviation [SD],  $52.85 \pm 2.92$  years) and body mass index (BMI) (22.97  $\pm$ 15 2.87 kg/m<sup>2</sup>) were relatively homogeneous. Mean BMD of the lumbar spine (L1-L4), 16 left total hip (HTOT, including femoral neck, trochanter, and inter-trochanter), 17 femoral neck (FN), and ultra-distal radius and ulna (UD-RU) were 1.05 g/cm<sup>2</sup>, 0.93 18 g/cm<sup>2</sup>, 0.86 g/cm<sup>2</sup>, and 0.40 g/cm<sup>2</sup>, respectively. Based on WHO criteria, 54.5% of the 19 subjects had normal BMD (T-score  $\geq$  -1), 38.5% osteopenia (-2.5  $\leq$  T-score  $\leq$  -1), and 20 7% OP (T-score  $\leq$  -2.5). Lifestyle factors (e.g., alcohol consumption, smoking, 21 calcium supplementation, exercise) and socioeconomic status (e.g., education and 22

- family annual income) are shown in Extended Data (ED) Table 1. Stool DNA and
- 2 blood samples were collected for metagenomic, genomic, and metabolomic analyses.

## Correlation between GM and BMD

- 5 We performed shotgun metagenomics sequencing on stool DNA samples and obtained
- 6 ~7.35 Gbp/sample sequencing data on average. We calculated unigene (non-redundant
- 7 genes) counts at different sample sizes. The number of unigenes increased with
- sample size, approaching a plateau (exceeded  $7 \times 10^6$ ) with our study sample (Figure
- 9 1a), indicating that our sample size was appropriate, large and reasonably powerful
- 10 for this investigation.

3

4

11

- 12 We identified 10,303 species by taxonomy annotation
- 13 (ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/nr.gz). 62 species were non-rare (relative
- abundance > 0.10%) <sup>11</sup> accounting for 61.02% of the whole GM. The rest were rare
- species (Figure 1b). The 3 most common species were Faecalibacterium prausnitzii
- 16 (8.77%), Bacteroides vulgatus (7.46%), and Bacteroides fragilis (4.16%). 26 and 27
- of the non-rare species had high positive (Spearman correlation coefficients  $[\gamma's] >$
- 18 0.80, p-values < 0.001) and negative ( $\gamma$ 's < -0.30, p-values < 0.001) correlations,
- 19 respectively, with one another (Figure 1c). This suggests that interactions between
- 20 GM species promote co-existence (when  $\gamma$  is > 0.80) or suppression (when  $\gamma$  is <
- 21 -0.30) of each other.

We used "vegan" package and Microbiome Regression-based Kernel Association Test 1 (MiRKAT) <sup>12</sup> to calculate  $\alpha$ -diversity (Shannon index) and  $\beta$ -diversity (optimal kernel, 2 3 based on weighted and unweighted UniFrac distance matrices and Bray-Curtis distance), and evaluated their associations with BMD. GM biodiversity was 4 negatively associated with forearm BMD (ED Table 2), including ultra-distal radius BMD (UD-R BMD, partial  $\gamma = -0.081$ , p-value = 0.072, p-value of MiRKAT = 0.005), 6 ultra-distal ulna BMD (UD-U BMD, partial  $\gamma = -0.098$ , p-value = 0.029, p-value of 7 MiRKAT = 0.014), and UD-RU BMD (partial  $\gamma = -0.097$ , p-value = 0.031, p-value of 8 9 MiRKAT = 0.010). The p-value significance remained when adjusted with false discovery rate for multiple testing (q-values  $\sim 0.10$  or less). Although no significant 10 association was found between GM biodiversity and BMD at L1-L4 or HTOT, we 11 12 hypothesized that individual bacterial species contributed to these phenotypes. 13 We performed constrained linear regression analysis <sup>13</sup>, and found several individual 14 15 species significantly associated with BMD (ED Table 3). Specifically, Bacteroides vulgatus (regression coefficient  $[\beta] = -0.027$ , p-value = 0.032), Bacteroides 16 thetaiotaomicron ( $\beta = 0.027$ , p-value = 0.021), Butyrate-producing bacterium SS3/4 17  $(\beta = -0.024, p\text{-value} = 0.040), Clostridium bolteae (\beta = 0.045, p\text{-value} = 0.036), and$ 18 Bacteroides sp 9 1 42faa ( $\beta = 0.033$ , p-value = 0.031) were associated with L1-L4 19 BMD. Additionally, Butyrate-producing bacterium SS3/4 was associated with HTOT 20 BMD ( $\beta = -0.022$ , p-value = 0.009) and FN BMD ( $\beta = -0.021$ , p-value = 0.014); 21 Bacteroides ovatus was associated with UD-RU BMD ( $\beta = 0.011$ , p-value = 0.046); 22

and Bacteroides intestinalis was associated with HTOT BMD ( $\beta = -0.021$ , p-value = 1 0.043). 2 3 After function annotation and obtaining KEGG modules, we performed partial Spearman correlation analysis to identify relationships between GM functional 4 5 capacity and BMD variation. Three functional modules were significantly negatively associated with L1-L4 BMD and four modules were negatively associated with 6 UD-RU BMD ( $\gamma$ 's < -0.10, p-values < 0.010) (Table 2). For example, for L1-L4 BMD, 7 significantly associated modules included "M00002: glycolysis, core module 8 9 involving three-carbon compounds", "M00048: inosine monophosphate biosynthesis, phosphoribosylpyrophosphate + glutamine  $\rightarrow$  inosine monophosphate", and "M00855: 10 glycogen degradation, glycogen → glucose-6P". All these modules involve pathways 11

whereby GM produces metabolites from ingested foods, suggesting that these

## SCFAs significantly associated with BMD

metabolites influence BMD.

12

13

14

15

16

17

18

19

20

21

22

GM may affect host health through SCFAs <sup>14</sup>. Therefore, we analyzed serum SCFA levels by targeted metabolomics. By multiple linear regression analysis, valeric acid was positively associated with L1-L4 BMD ( $\beta$  = 0.040, p-value = 0.029). The results (non-significant) of other kinds of SCFAs (including caproic acid, isovaleric acid, butyric acid, acetic acid, and isobutyric acid) were shown in ED Table 4. Furthermore, five bacterial species were significantly associated with valeric acid (ED Table 5). *Alistipes putredinis*, *Bacteroides caccae*, and *Bacteroides cellulosilyticus* were

positively associated with valeric acid ( $\beta$ 's > 0.05, p-values < 0.05, ED Table 5).

B.vulgatus and B.intestinalis, which were negatively associated with L1-L4 and

HTOT BMDs (ED Table 3), were also negatively associated with valeric acid (β's <

4 -0.10, p-values < 0.01, ED Table 5). Since only B.vulgatus was significantly

associated with both L1-L4 BMD and valeric acid, we subsequently focused on this

6 species.

2

3

5

7

10

11

12

13

14

15

16

17

18

19

20

21

8 Since valeric acid is produced by probiotic bacteria <sup>15</sup>, we calculated the Spearman

9 correlation between *B.vulgatus* and common probiotic bacteria <sup>16, 17</sup>. The relative

abundance of *B. vulgatus* was negatively associated ( $\gamma = -0.24$ , p-value =  $8.3 \times 10^{-8}$ )

with the sum of relative abundance of common probiotic bacteria (each still rare (<

0.10%) so pooled for analyses). We used Mendelian randomization (MR) approach <sup>18</sup>

to assess the potential causality of B.vulgatus (as exposure) on valeric acid (as

outcome), using their associated SNPs derived from whole genome sequencing for

human subjects as instrumental variables. Most MR methods, including the weighted

median method, maximum likelihood estimation, and inverse-variance weighted

indicated that *B.vulgatus* may causally down-regulate valeric acid ( $\beta$ 's < -0.07,

p-values < 0.05) (ED Table 6). MR-Egger (intercept) result (p-value = 0.517) showed

no horizontal pleiotropy for *B.vulgatus* to influence valeric acid levels.

## B.vulgatus/BMD associations in US Caucasians

22 To assess the robustness of our major findings, we tested associations between

B.vulgatus and human BMD in an independent cohort of 59 post-menopausal
 Caucasian females, aged ≥ 60 years, in New Orleans, Louisiana. Mean (SD) age and
 BMI were 66.98 (5.65) years and 27.84 (8.50) kg/m², respectively. Mean BMD for

4 L1-L4, HTOT, FN, UD-R, and UD-U were 0.92 g/cm<sup>2</sup>, 0.80 g/cm<sup>2</sup>, 0.67 g/cm<sup>2</sup>, 0.37

5 g/cm<sup>2</sup>, and 0.28 g/cm<sup>2</sup>, respectively. Lifestyle information is shown in ED Table 7. We

detected an association between B.vulgatus and HTOT BMD ( $\beta = -0.018$ , p-value =

0.029), supporting B.vulgatus's association with BMD in ethnically distinct

8 populations.

## In vivo and in vitro validation

To evaluate potential causal effects of *B.vulgatus* on bone metabolism (focusing on lumbar vertebrae), we ovariaectomized (OVX) 8-week-old female C57BL/6 mice (n = 18) to model post-menopause, and performed oral gavage experiments. After gavaging with *B.vulgatus*/normal saline (NS) for eight weeks after OVX, we found lower BMD (*p*-value < 0.05, Figure 2a), increased disconnection and separation of the trabecular bone network, and reduction of trabecular number (Figure 2d and Figure 2e) in the *B.vulgatus* treated group. The *B.vulgatus* treated group also showed lower (two-sample t-test, *p*-value < 0.05) bone formation levels (measured by serum osteocalcin, Figure 2b) and higher (two-sample t-test, *p*-value < 0.05) bone resorption levels (measured by type I collagen serum C-telopeptide, Figure 2c). This demonstrates that *B.vulgatus* suppressed bone formation and promoted bone resorption leading to reduced lumbar vertebral BMD and deteriorated bone

architecture.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Since our results suggested that B.vulgatus affects BMD by down-regulating valeric acid production, we investigated the effects of valeric acid on osteoclast and osteoblast differentiation in vitro. Murine macrophages (RAW264.7) pre-osteoblasts (MC3T3-E1) were differentiated with/without valeric acid. After inducing osteoclast differentiation of RAW264.7 cells with RANKL (50 ng/mL), 5 days treatment with valeric acid (1 mM) significantly decreased the proportion of mature osteoclast-like cells (TRAP positive and with > 3 nuclei) vs. controls (Figure 3a), indicating that valeric acid significantly inhibited osteoclast differentiation. Treatment with valeric acid (1 mM) for 14 days also significantly increased differentiation of MC3T3-E1 into osteoblasts, and mineralization of the extracellular matrix (Figure 3b). Therefore, valeric acid inhibited differentiation of osteoclast-like cells, and promoted differentiation of, and mineralization by, osteoblasts. Because inflammatory pathways play important roles in bone metabolism <sup>19</sup> and GM may influence bone metabolism through its effects on inflammation 4, we measured expression levels of several critical inflammatory genes (e.g., NF-κB p65 and IL-10) in cultured osteoclast-like cells and osteoblasts. After treating osteoclast-like cells and osteoblasts with valeric acid for 5 and 14 days, respectively, IL-10 (anti-inflammatory cytokine) mRNA levels were significantly increased, while NF-κB p65 (pro-inflammatory) protein levels were decreased, compared to controls (Figures 3c to

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

3f). NF-κB p65 is a subunit of NF-κB, plays a critical role in the pathogenesis of multiple chronic inflammatory diseases by upregulating transactivation of inflammatory cytokines target genes <sup>20</sup>; while IL-10 is an anti-inflammatory cytokine <sup>21</sup>. Thus, valeric acid inhibited inflammatory responses of osteoclast-like cells and osteoblasts, which may explain its positive association with BMD, since inflammation may lead to bone loss <sup>19</sup>, and the NF-κB can inhibit osteoblast functions <sup>22</sup>. **Discussion** We found that: 1) GM biodiversity was negatively associated with forearm BMD; 2) several individual bacterial species were significantly associated with BMD; 3) B. vulgatus was negatively associated with BMD in ethnically distinct populations; 4) several bacterial metabolic pathways were negatively associated with BMD; 5) serum valeric acid levels were positively associated with L1-L4 BMD; 6) B.vulgatus was negatively associated with serum valeric acid levels; and 7) B. vulgatus may causally suppress valeric acid levels, presumably by inhibiting growth of valeric acid producing bacteria within the gut. Subsequent in vivo and in vitro studies found that 1) bone formation was decreased, and bone resorption increased, in OVX female mice fed B.vulgatus; 2) valeric acid suppressed maturation of osteoclast-like cells, and promoted maturation of osteoblasts and extracellular matrix mineralization by osteoblasts in vitro; 3) valeric acid treatment of osteoclast-like cells and osteoblasts in vitro suppressed NF-κB p65

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

protein production (pro-inflammatory), and enhanced IL-10 mRNA expression (anti-inflammatory). Thus, B. vulgatus appears to decrease BMD by reducing valeric acid production within the gut, resulting in enhanced inflammation and osteoclast activity, and reduced osteoblast activity. The negative association between GM biodiversity and BMD in our discovery sample is consistent with previous reports. Wang et al. found elevated diversity in OP and osteopenia groups compared with controls 8, and Das et al. found a trend of higher Shannon index (α-diversity) in OP and osteopenia groups compared with controls (Fig 3D in 6) 6. Germ-free mice (no GM biodiversity exists) had higher bone mass than mice with normal GM 5, and that antibiotic treatment of mice early in life reduced GM biodiversity and increased bone size <sup>23</sup>. Although GM biodiversity is generally believed to be beneficial <sup>24</sup>, the above results suggest that the effects of GM biodiversity on health vary with the trait studied, environmental factors (e.g. diet and exercise) and individual species composition within GM. In our study, B. vulgatus was negatively associated with L1-L4 BMD in the Chinese cohort ( $\beta = -0.027$ , p-value = 0.032), which has a consistent association with HTOT BMD in the US cohort ( $\beta = -0.018$ , p-value = 0.029). In fact, B.vulgatus tended to be consistently negatively (though non-significantly in many cases) associated with BMDs at all the measured various other skeletal sites in both of the two human cohorts (ED Table 8). To evaluate the overall effects of B.vulgatus on BMD, we

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

further performed one-sided sign test 25 based on the coefficients of the regression of individual skeletal sites with *B. vulgatus* (ED Table 8). The null hypothesis (H0) is that regression coefficients are equal to zero. The alternative hypothesis (H1) is that regression coefficients are less than zero. The results indicated clearly that overall, there were significant negative associations between BMDs and B.vulgatus in both of the Chinese and the US cohorts (p-value Chinese =  $4.8 \times 10^{-7}$ , p-value US = 9.8 $\times$  10<sup>-4</sup>). In genomics studies, it is not uncommon to observe that a particular gene was significantly associated with different skeletal sites of BMDs in different populations. An example is given by the most prominent WNT16 gene, which was found to be associated with BMD at different skeletal sites in different cohorts <sup>26</sup>. The association and partial validation between B.vulgatus and BMD in the human cohorts was only mainly for discovery relative to the following-up functional validation studies. Following discoveries in humans, we subsequently validated the results by various in vivo and in vitro experiments. All of the results together furnish strong evidence for the significance of *B.vulgatus* on BMD and bone metabolism. B.vulgatus is one of the most abundant bacteria in human gut <sup>27</sup>, and can trigger proinflammatory NF-κB signaling pathways <sup>27</sup> associated with bone remodeling <sup>28</sup>. To determine how GM influences BMD, we examined relationships between GM functional capacity and BMD variation. Most GM functional modules negatively associated with BMD (Table 2) involved GM metabolism. M00002, M00003 and M00855 involved glycolytic pathways or gluconeogenesis, both of which affect

glucose metabolism, essential for cellular energy <sup>29</sup>. Modules M00048 and M00050

both involve nucleic acid synthesis required for bacterial growth 30, 31. These

collective findings demonstrate that human bone health is affected by GM, and that

specific bacterial biosynthetic/metabolic pathways, contribute to these effects.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Since several GM functional modules were associated with BMD, and microbial metabolites contribute to host-microbiome interactions <sup>32</sup>, we explored relationships between BMD and serum SCFAs. SCFAs are produced exclusively by GM <sup>15</sup>, absorbed in the colon <sup>15</sup>, and function as critical signalling molecules between the host and GM <sup>15</sup>. Regarding the potential impact of SCFAs on bone health, butyrate has been reported to inhibit osteoclast differentiation and bone resorption in mice 14, 33. In the current study, we found that valeric acid (an SCFA) was positively associated with BMD, inhibited differentiation of osteoclast-like cells, and promoted differentiation and mineralization of osteoblasts. Valeric acid also suppressed NF-κB p65 protein production (pro-inflammatory), and enhanced expression of IL-10 mRNA (anti-inflammatory) by osteoclast-like cells and osteoblasts. This is consistent with previous reports that SCFAs reduced macrophage induced inflammation by suppressing NF-κB, and increasing IL-10, expression <sup>34</sup>. IL-10 inhibits NF-κB production <sup>35</sup>, and NF-κB promotes inflammation, which contributes to bone loss <sup>19</sup>, and inhibits osteoblasts, which reduces new bone formation 22. These collective results are consistent with the conclusion that the protective effect of valeric acid on BMD is partially attributable to decreased osteoclast activity and increased osteoblast

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

activity through increased IL-10 expression, and direct (via valeric acid) or indirect (via IL-10) inhibition of NF-κB expression <sup>28</sup>. Valeric acid inhibits histone deacetylase (HDAC), an enzyme that is important for epigenomic regulation of gene expression <sup>36</sup>. HDAC is implicated in the pathogenesis of a number of diseases (e.g., cancer, colitis, cardiovascular disease and neurodegeneration), and HDAC inhibitors are considered as potential therapeutic agents <sup>36</sup>. In irradiated mice, valeric acid can protect hematogenic organs, improve gastrointestinal tract function and enhance intestinal epithelial integrity to elevate survival rate <sup>37</sup>. Our study here for the first time suggest that valeric acid could be used to treat/prevent OP. Since both B.vulgatus and valeric acid were associated with BMD, we sought to determine whether B.vulgatus regulated bone metabolism by decreasing valeric acid levels. Regression and MR analyses demonstrated that B.vulgatus was negatively associated with valeric acid, and may causally down-regulate valeric acid levels. We also observed negative correlations between B.vulgatus and common gut probiotic bacteria <sup>16, 17</sup>. Bacterial fermentation product levels (e.g., valeric acid) depend on the relative abundances of different GM populations, and on competitive and cooperative interactions between different GM species <sup>38</sup>. GM in humans is dominated by negative interactions, and the *Bacteroidales*, which includes *B.vulgatus*, commonly express molecular mechanisms for delivering toxic payloads to other bacteria <sup>39</sup>. Consequently, we speculate that B.vulgatus competitively inhibits growth of valeric acid producing probiotic bacteria, thereby reducing valeric acid levels.

2

3

4

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

In this study, we pioneered an innovative and comprehensive multi-omics approach for discovery in a Chinese cohort, followed by in vitro and in vivo functional validation experiments plus replication in an independent cohort of US Caucasians. We, for the first time, successfully identified and validated individual gut bacterial species, and their derived metabolites, that were significantly associated with human BMD. These findings provide a potential novel target and pathway for OP prevention and treatment during the critical menopausal period in aging women. There are several strengths of our study. First, to our knowledge, this is currently the largest metagenomics study directly testing associations between GM and human BMD. Second, we used stringent inclusion and exclusion criteria to ensure that subjects were relatively homogeneous for age, ovarian function and living environment, thereby minimizing potential confounding factors. Third, functional mechanisms contributing to associations between GM and BMD were identified by using an innovative multi-omics approach to generate a comprehensive understanding of crosstalk, interactions, and causal inference of the interactions, between GM and human BMD. Finally, we used both statistical and experimental evidences to demonstrate the effects of specific bacterial species and GM-derived metabolites on BMD variation and regulation, and the causal effects of specific gut bacterial species on GM-derived metabolites in human serum.

In conclusion, our study provides compelling evidence for associations between GM, 1 SCFAs and human BMD. Importantly, we demonstrated that B.vulgatus appears to 2 3 play a critical role in regulating bone metabolism, through its effects on valeric acid production. Valeric acid, in turn, promotes differentiation and mineralization of 4 5 osteoblasts, and suppresses osteoclast differentiation and inflammatory responses by osteoblasts and osteoclast-like cells. Our findings provide novel insights into the 6 pathophysiological mechanisms of OP from a novel perspective of human microbiota 7 and their functional products, SCFAs, in human serum and suggested potential new 8 9 biomarkers (e.g., valeric acid) and treatment targets (e.g., elimination of B.vulgatus OP 10 from the gut; dietary supplementation with valeric acid) for prevention/intervention/treatment. 11

## **Online Methods**

12

13

14

15

16

17

18

19

20

21

22

## Subjects recruitment and sample preparation

This study was approved by the Third Affiliated Hospital of Southern Medical University (Guangzhou City, China). It was performed under the principle of the Helsinki Declaration II. 517 independent unrelated peri-/post-menopausal Chinese women were recruited. The inclusion criteria included 1) aged 40 years or older, 2) being in menopause stage, and 3) had lived in Guangzhou City for at least three months. Menopause is marked by the cessation of menstruation, where peri-menopause is a transition phase beginning at a woman's last menstrual cycle and continuing through the following 12 months without a menstrual cycle; once there are

2

3

4

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

no menstrual cycles for 1 year, we term it post-menopause <sup>10</sup>. Briefly, exclusion criteria included the use of antibiotics, oestrogens, or anticonvulsant medications which may affect gut microbiota (GM) composition and/or bone metabolism in the past three months, as well as other diseases that could lead to secondary osteoporosis (OP). A detailed list of exclusion criteria is shown in Extended Data (ED) Table 9. We obtained signed informed consent from each subject before enrolling them into this study. Each subject filled out a questionnaire that collected information on age, medical history, family history, physical activity, alcohol consumption, diet habits, smoking history, nutrition supplements, etc. We used a GE Lunar dual energy X-ray absorptiometry (DXA, GE Healthcare, Madison, WI, USA, version 13.31.016) with a standard scan model to measure the bone mineral density (BMD) of each subject at various skeletal sites, including the lumbar spine (L1-L4), left total hip (HTOT), femoral neck (FN), ultra-distal radius and ulna (UD-RU). We performed DXA scanner calibration with a daily special phantom scan for quality assurance. The accuracy of various skeletal sites BMD measurement was assessed by the coefficient of variation (CV%) of spine BMD, which was 0.89%. Blood and stool samples were collected from each subject. Blood samples were collected after an overnight fast for > 8 hours, and used for serum analysis and DNA extraction with the SolPure DNA Kit (Magen, Guangzhou, China). Each faecal sample was frozen at -80 °C within 30 min of sample procurement, and used for GM DNA extraction with the E.Z.N.A.® Stool DNA Kit (Omega, Norcross, GA, USA).

1 We stored the serum, blood and GM DNA samples at -80 °C until further analyses.

## Metagenomic shotgun sequencing and annotation

4 DNA library construction

2

3

- 5 Shotgun metagenomic sequencing was performed by LC-Bio Technologies
- 6 (Hangzhou) CO., LTD. (Hangzhou, China, www.lc-bio.com; this company owns an
- 7 LC Sciences R&D department in Houston, TX, USA, www.lcsciences.com). We
- 8 constructed a faecal DNA library, and used Hiseq 4000 (Illumina, San Diego, CA,
- 9 USA) and PE150 strategy to conduct metagenomic shotgun sequencing. The relative
- abundance of unigenes for a sample was estimated by transcripts per kilobase million
- 11 (TPM, Formula 1, where k was the k<sup>th</sup> unigene, r was number of unigene reads, and L
- was unigene length) based on the number of aligned reads and the unigene length by
- 13 Bowtie2 v2.2.0.

14 
$$G_k = \frac{r_k}{L_k} \times \frac{1}{\sum_{i=1}^n \frac{r_i}{L_i}} \times 10^6 \quad (1)$$

- 16 Taxonomic and functional annotation of unigenes
- 17 The unigenes were aligned against the NCBI NR database
- 18 (ftp://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/nr.gz) by DIAMOND software 40 with
- 19 lowest common ancestor algorithm 41 for taxonomic annotation, and against protein
- 20 reference based on the KEGG pathway dataset
- 21 (https://www.genome.jp/kegg/pathway.html) for functional annotation. The relative
- 22 abundance of each annotated functional module was the sum of relative abundance of

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

the unigenes within this module. We chose the modules whose relative abundance > 0.10% to estimate the association between the KEGG modules and BMD variation by performing partial Spearman correlation analysis, and adjusted for a number of covariates, including age, body mass index (BMI), years since menopause (YSM), follicle stimulating hormone (FSH), exercise, and family annual income. Results with *p*-values < 0.01 were considered statistically significant. Detailed information about faecal DNA library construction, raw data preprocessing and cleaning, taxonomic and functional annotation of unigenes, was shown in supplementary information. Unigene accumulation curve construction and species biodiversity calculation We first counted the number of unigenes at different sample sizes. The R package "ggplot2" was used to generate a unigene accumulation curve. We plotted the number of unigenes (Y-axis) against the number of samples (X-axis). The  $\alpha$ -diversity of GM was estimated based on the species profile of each sample according to the Shannon index by using R package "vegan". Then, partial Spearman correlation analysis was performed to estimate the association between the Shannon index and BMD variation. The association between bacterial species profiles and BMD variation was calculated by the program Microbiome Regression-based Kernel Association Test (MiRKAT) 12, by which we first calculated different kinds of kernels (including weighted and unweighted UniFrac distance matrices and Bray-Curtis distance), and then obtained the optimal kernel to estimate the association between

1 GM species profiles and BMD variations. In these analyses, we adjusted the same set

of covariates as the KEGG modules analysis mentioned above. Results with p-values

less than 0.05 were considered statistically significant.

2

3

4

7

9

10

13

14

15

16

17

18

19

20

21

22

## Measurement of short chain fatty acids (SCFAs)

6 2 μl of the supernatants extracted from serum samples were analyzed with gas

chromatography-tandem mass spectrometry (GC-MS/MS, 7890B-7000D, Agilent

8 Technologies Inc, Santa Clara, CA, USA) by Wuhan Metware Biotechnology Co., Ltd

(Wuhan City, China, www.metware.cn) based on a fused silica capillary column

(DB-FFAP, 30 m x 0.25 mm x 0.25 µm, Agilent Technologies Inc, Santa Clara, CA,

USA). Then we constructed standard curves to calculate concentration of SCFAs.

12 Detailed conditions of GC-MS/MS, quality control (QC), preparation of SCFAs

calibration standards, and SCFAs concentration calculation by standard curves, were

shown in supplementary information.

## Association analysis among GM, SCFA, and BMD

We treated BMD as a continuous variable and then explored the association among

GM, SCFA, and BMD by using different association analysis methods. In this study,

we focused on non-rare species (relative abundance > 0.10%) because rare species

typically contribute significantly less to functional diversity than non-rare species due

to their low abundances <sup>42</sup>; meanwhile, the rare species are generally difficult to

cultivate 42, which might make our subsequent experimental validation in vivo

difficult. 1 For the association analysis, first, we used the "igraph" package and the "psych" 2 3 package of R software to identify correlations between bacterial species. Spearman correlation analysis was performed on the relative abundance of each bacterial species. 4 5 Meanwhile, we used the same method to identify correlations between specific bacterial species and probiotic bacteria reported in two previous reviews which 6 summarized the most notable probiotics <sup>16, 17</sup>. The reported probiotic bacteria were 7 pooled for such analyses due to the small relative abundances of each of the 8 individual species (less than 0.10%). Furthermore, the R package "pheatmap" 9 package was used to create a heatmap for visualization of the bacterial species 10 correlation. 11 12 Second, for those highly correlated bacterial species (with correlation coefficients  $[\gamma's]$  $\geq 0.80$ ) that might cause a multiple co-linearity problem, we retained the bacterial 13 species with a higher relative abundance and removed others as bacteria with 14 15 relatively higher relative abundance may render higher power in association testing. Constrained linear regression analysis 13 was then performed by using Stata 14 16 software with the "cnsreg" function, in which BMD variation was considered as the 17 dependent variable, and the relative abundance of bacterial species was set as the 18 independent variable. A number of covariates were adjusted in the regression analysis, 19 including age, BMI, YSM, FSH, exercise, and family annual income. The threshold of 20 exercise was 2.5 hours per week based on a published guideline 43. The family annual 21 income was separated according to the local economic report. As microbiome data are 22

- often obtained at different taxonomic ranks (including species, genus, family, order,
- 2 class and phylum), we performed subcomposition analysis using previously published
- 3 protocols <sup>13</sup>, and converted the bacterial species relative abundance data into
- 4 subcompositions within each phylum by centered log ratio transformation, to find out
- 5 which bacterial species within a given phylum is associated with BMD variation. The
- 6 formula of constrained linear regression analysis is shown below (Formula 2), where
- p was the phylum level, n was the number of phyla, s was species level, and m was
- 8 the number of bacterial species. Bacterial species with a p-value of the regression
- 9 coefficient (β) less than 0.05 were defined as BMD-associated bacterial species.

$$Y(BMD) = \sum_{p=1}^{n} \sum_{s=1}^{m} \beta_{ps} CLR(X_{ps}) + \beta * covariates$$

$$\sum_{s=1}^{m} \beta_{ps} = 0$$
(2)

- 11 Third, we used multiple linear regression analysis to identify BMD-associated SCFAs
- 12 (Formula 3), where we performed log transformation for the SCFA concentration
- 13 because of their non-normalization distribution and adjusted the same set of
- 14 covariates mentioned above.

15 
$$Y(BMD) = \sum \beta_i * log(X_i) + \beta_j * covariates_j$$
 (3)

- 16 Finally, we performed constrained linear regression analysis (Formula 4) to identify
- 17 SCFA-associated bacterial species, while adjusting for age, BMI, YSM, and FSH as
- 18 covariates.

$$Y(\log(\text{individual SCFA})) = \sum_{p=1}^{n} \sum_{s=1}^{m} \beta_{ps} \text{CLR}(X_{ps}) + \beta * \text{covariates}$$

$$\sum_{s=1}^{m} \beta_{ps} = 0$$
(4)

Replication in the Caucasian cohort 2 3 A total of 59 Caucasian females, aged 60 years or older, were recruited from the ongoing Louisiana Osteoporosis Study (from 2011 to current), which aims to build a 4 5 large sample pool in greater New Orleans and surrounding areas in Southern Louisiana, USA for investigating genetic and environmental 6 musculoskeletal disorders 44. This study was approved by the institutional review 7 board of Tulane University (New Orleans, LA, USA), and a written consent form was 8 9 signed by each participant before data and bio-sample collection. Individuals who had pathological conditions that may influence BMD (e.g., a bilateral oophorectomy, 10 11 chronic renal failure, liver failure, lung disease, gastrointestinal diseases, and inherited 12 bone diseases), or may influence GM (e.g., taking antibiotics, having gastroenteritis, major surgery involving hospitalization, and inter-continental travel in the past three 13 months) were excluded. For each participant, BMD was measured by using a Hologic 14 15 Discovery-A DXA machine (Hologic Inc., Bedford, MA, USA) and information on age, medical history, physical activity, alcohol consumption, diet habits, smoking 16 history, and nutrition supplements was assessed by a questionnaire. The accuracy of 17 BMD measurement as assessed by the CV% of L1-L4 BMD was 0.54%. The shotgun 18 metagenomics sequencing on the collected faecal samples were performed by Alkek 19 Center for Metagenomics and Microbiome Research (CMMR), Baylor College of 20 Medicine. We conducted partial Spearman correlation analysis for the identification of 21 correlation between GM biodiversity and BMD variation, and we also used 22

- 1 constrained linear regression analysis (Formula 2), as described above, to identify
- 2 BMD-associated individual bacterial species. The covariates included age, BMI,
- 3 exercise, and bone fracture.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

## In vivo mouse experiment with B.vulgatus

6 Ovariectomy (OVX) and B.vulgatus gavage

7 All the procedures involving mice were approved by the Southern Medical University

Animal Management Committee (Guangzhou City, China). Seven-week-old female

C57BL/6 mice (specific-pathogen free grade) were purchased from the Laboratory

Animal Center of the Southern Medical University (Guangzhou, China). The mice

were fed freely with food and water for one week to acclimate to the new

environment before experiments. Then bilateral OVX surgery was performed with

general anaesthesia by the dorsal approach because eight-week-old C57BL/6J mice

are suitable animal model for postmenopausal osteoporosis 45. After one week for

recovery, the mice were separated randomly into two groups (9 samples/group):

Group I mice were gavaged with 100  $\mu$ l of B.vulgatus (ATCC8482, 5  $\times$  10<sup>8</sup>

colony-forming units/mouse, ATCC, Manassas, VA, USA; lot number: 70009621),

while Group II mice were gavaged with 100 µl of normal saline (NS). B. vulgatus was

cultivated according to the product description and harvested in log phase for gavage.

All mice were gavaged every other day and continued to feed freely with common

food and water under the same environmental conditions. After gavaging for eight

weeks, the mice were sacrificed and used for blood and bone measurements.

1 BMD measurement and bone morphology evaluation by micro-computed tomography 2 3  $(\mu CT)$ We used LaTheta LCT 200 µCT (Aloka, Japan) to measure the BMD of the 5<sup>th</sup> lumbar 4 vertebral body. The instrument accuracy was  $1 \pm 0.005$  mg/cm<sup>3</sup>. We performed 5 phantom scan at first for QC. Then we scanned the lumbar spine to obtain lumbar 6 vertebral body BMD. Meanwhile, for visualization and comparison of bone 7 microstructure changes, we randomly selected a bone sample (the 5<sup>th</sup> lumbar vertebrae) 8 from each of the two mice groups (Group I with B.vulgatus gavage and Group II with 9 NS gavage), and used µCT100 (Scanco Medical AG, Bassersdorf, Switzerland) with a 10 resolution of 7.4 µm for three-dimensional reconstruction. 11 12 Analysis of serum biomarkers 13 We used ELISA kits to measure osteocalcin (Cloud-Clone Corp, Katy, TX, USA) and 14 15 C-telopeptide of type I collagen (Cusabio, Houston, TX, USA), which are markers of bone formation and bone resorption, respectively. 16 17 Histomorphometry 18 We used hematoxylin-eosin (ZSGB-BIO, Beijing, China) staining to assess 19 histomorphology of trabecular bone in the 5<sup>th</sup> lumbar vertebrae. 20 21

Statistical analysis

- 1 We used two-sample t-test to identify whether BMD and serum biomarkers were
- 2 significantly different between the two groups.
- 3 Details about scanning parameters of  $\mu$ CT and histomorphometry process were shown
- 4 in supplementary information.

11

- 6 Mendelian randomization (MR) analysis for BMD-associated GM and SCFA
- 7 Whole genome sequencing (WGS)
- 8 WGS was performed by BGI Genomics Co. Ltd (Shenzhen, China;
- 9 https://www.genomics.cn/) with BGISEQ-500 platform.
- Details including quality control were shown in supplementary information.
- 12 Genome-wide association study (GWAS)
- We used PLINK 1.9 software with the default criteria as follows to identify *B.vulgatus*
- and valeric acid-associated SNPs: the SNPs with missing call rate < 0.1, minor allele
- frequencies > 0.01, and Hardy-Weinberg equilibrium p-value  $> 1.0 \times 10^{-5}$  were
- included for subsequent analyses.
- 18 MR analysis
- 19 Based on B.vulgatus and valeric acid GWAS results, we investigated the causality of
- 20 B. vulgatus exposure on valeric acid outcome with one-sample MR analysis, which is
- a commonly used method. One-sample MR analysis uses genetic variants, exposure,
- and outcome from the same individua, which provides greater control of the analysis

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

(such as determining exposure category - a continuum or in categories, examining associations between genetic instruments and confounders) than two-sample MR analysis 46. For the implementation of MR, we first selected independent genetic variants ( $r^2 < 0.001$ ) associated with the B.vulgatus (p-values  $< 1 \times 10^{-5}$ ) as the instrumental variables (IVs) as done earlier <sup>47</sup>. We then obtained the corresponding effect estimates of these SNPs from the valeric acid GWAS analysis. When the target SNPs were not available in the valeric acid GWAS result, we used proxy SNPs that were in high linkage disequilibrium (LD,  $r^2 > 0.80$ ) with the SNPs of interest. The proxy SNPs were identified based on 1000 genomes project data <sup>48</sup>. To ensure the SNPs used as IVs for *B.vulgatus* are not in LD with one aother, a vital assumption of MR, we calculated pairwise-LD between all of our selected SNPs in the 1000 Genomes European reference sample using PLINK 1.9. For all the pairs of SNPs determined to violate the independence assumption with  $r^2 > 0.01$ , we retained only the SNPs with the smaller B.vulgatus association p-values. Overall, we obtained 15 LD-independent SNPs that achieved genome-wide significance for B.vulgatus and valeric acid. Therefore, these 15 SNPs remained for performing the MR analysis (Extended Data Table 10). Weighted median method, maximum likelihood estimation (MaxLik) and inverse-variance weighted (IVW) <sup>49</sup> were performed to identify causal relationships between B.vulgatus and valeric acid by weighting the effect estimate of each SNP on valeric acid with its effect on B.vulgatus. Because SCFA was only produced from GM <sup>14</sup>, we only chose single direction MR (B.vulgatus as exposure and valeric acid as outcome) rather than bidirectional MR analysis. Because the

- presence of horizontal pleiotropy could bias the MR estimates, we used the intercept
- 2 that deviates from the MR-Egger method to examine the presence of horizontal
- 3 pleiotropy as described in the previous study <sup>47</sup>.

5

20

## Effects of valeric acid on osteoclastogenesis and osteoblastogenesis

- 6 In vitro differentiation of osteoclast-like cells
- 7 We used the murine monocyte/macrophage cell line RAW264.7 (Chinese Academy of
- 8 Sciences Cell Bank, Shanghai, China) as osteoclast precursors, which can
- 9 differentiate into osteoclast-like cells in the presence of receptor activator of nuclear
- 10 factor-κB ligand (RANKL, 50 ng/mL, PEPROTECH, Rocky Hill, NJ, USA). The
- 11 cells were grown in Dulbecco's Modified Eagle Medium (DMEM,
- 12 GIBCO/Invitrogen, Carlsbad, CA, USA), containing 10% fetal bovine serum (FBS,
- 13 GIBCO/Invitrogen, Carlsbad, CA, USA), 100 U/ml penicillin and 100 mg/ml
- streptomycin sulfate (GIBCO/Invitrogen, Carlsbad, CA, USA), at 37°C in a
- 15 humidified atmosphere of 95% air and 5% CO<sub>2</sub>, and treated with various
- 16 concentrations (0, 0.001, 0.01, 0.1, 1 mM) of valeric acid (TCI, Tokyo, Japan). We
- 17 changed the medium every other day, and fixed the cells at the end of the 5<sup>th</sup> day.
- 18 Then we performed tartrate-resistant acid phosphatase (TRAP) staining (Solarbio,
- 19 Beijing, China) to observe TRAP-positive multinucleated (≥ 3 nuclei) cells.
- 21 In vitro differentiation of osteoblasts
- 22 MC3T3-E1 cells (Chinese Academy of Sciences Cell Bank, Shanghai, China) were

maintained in osteoblastogenic medium (AAPR99-C500, Pythonbio, Guangzhou,

China) with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin sulfate at

37°C with 5% CO<sub>2</sub>, and treated with various concentrations of valeric acid (0, 0.001,

4 0.01, 0.1, 1 mM) for 14 days. Then alkaline phosphatase (Beyotime, Shanghai, China)

staining and alizarin red S (Solarbio, Beijing, China) staining were performed

according to standard techniques to evaluate osteoblast differentiation and

extracellular matrix mineralization, respectively.

## Gene expression in osteoclast-like cells and osteoblasts

Total protein and RNA were extracted from osteoclast-like cells and osteoblasts to examine expression of the selected genes. Protein concentration was determined by the BCA protein assay kit (Thermo scientific, Rockford, IL, USA). Since NF- $\kappa$ B signaling pathway was reported to activate osteoclastogenesis <sup>28</sup> and inhibit osteoblastogenesis <sup>22</sup>, and SCFAs can suppress this pathway <sup>34</sup>, we explored whether the suppressive effect and stimulating effect of valeric acid on osteoclast-like cells and osteoblasts, respectively, were at least partially through inhibition of the NF- $\kappa$ B signaling pathway. Western blot (WB) analysis was performed with NF- $\kappa$ B signaling pathway-associated primary antibody targeting NF- $\kappa$ B p65 (Bclonal, Beijing, China) in osteoclast-like cells and osteoblasts, and GAPDH (Proteintech, Chicago, IL, USA) was used as a reference protein. After validating the association between valeric acid and the NF- $\kappa$ B signaling pathway, we further explored whether IL-10 in osteoclast-like cells and osteoblasts contributed to this association. We examined

- 1 IL-10 because it can be increased by SCFAs <sup>34</sup> and inhibit activation of NF-κB <sup>35</sup>.
- 2 Real-time PCR analysis (SYBR green real time PCR master mix, TOYOBO, Osaka,
- 3 Japan) was performed for the transcriptional levels of IL-10. Relative expression of
- 4 IL-10 was normalized to mouse-18S expression, and calculated using the comparative
- 5 threshold cycle (Ct) method <sup>50</sup>. The primers of IL-10 were
- 6 GGAGCTGAGGGTGAAGTTTGA (sense) and GACACAGACTGGCAGCCAAA
- 7 (antisense). The primers of mouse-18S were CGATCCGAGGCCTCACTA (sense)
- 8 and AGTCCCTGCCCTTTGTACACA (antisense).

## Online resources and abbreviations

9

10

12

Online resources and abbreviations are provided in supplementary information.

perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

References:

- 3 1. Singer, A., et al.. Burden of illness for osteoporotic fractures compared with other serious diseases
- 4 among postmenopausal women in the United States. MAYO CLIN PROC 90, 53-62 (2015).
- 5 2. Khosla, S., et al.. Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. J
- 6 BONE MINER RES **32**, 424-430 (2017).
- 7 3. Hendrickx, G., Boudin, E. & Van Hul, W. A look behind the scenes: the risk and pathogenesis of
- 8 primary osteoporosis. NAT REV RHEUMATOL 11, 462-474 (2015).
- 9 4. Chen, Y.C., Greenbaum, J., Shen, H. & Deng, H.W. Association Between Gut Microbiota and
- 10 Bone Health: Potential Mechanisms and Prospective. J CLIN ENDOCR METAB 102, 3635 (2017).
- 5. Sjogren, K., et al.. The gut microbiota regulates bone mass in mice. J BONE MINER RES 27,
- 12 1357-1367 (2012).

1

- 13 6. Das, M., et al.. Gut microbiota alterations associated with reduced bone mineral density in older
- 14 adults. Rheumatology (Oxford) (2019).
- 15 7. Per-Anders Jansson, et al. Probiotic treatment using a mix of three Lactobacillus strains for
- lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled,
- multicentre trial. *The Lancet Rheumatology* **3**, E154-E162 (2019).
- 18 8. Wang, J., et al.. Diversity analysis of gut microbiota in osteoporosis and osteopenia patients.
- 19 *PEERJ* **5**, e3450 (2017).
- 20 9. Nilsson, A.G., Sundh, D., Backhed, F. & Lorentzon, M. Lactobacillus reuteri reduces bone loss in
- 21 older women with low bone mineral density: a randomized, placebo-controlled, double-blind, clinical
- 22 trial. J INTERN MED 284, 307-317 (2018).
- 23 10. Lumsden, M.A. The NICE Guideline Menopause: diagnosis and management. CLIMACTERIC
- **19**, 426-429 (2016).
- 25 11. Aguilar, P., Dorador, C., Vila, I. & Sommaruga, R. Bacterioplankton composition in tropical
- high-elevation lakes of the Andean plateau. FEMS MICROBIOL ECOL 94(2018).
- 27 12. Zhao, N., et al.. Testing in Microbiome-Profiling Studies with MiRKAT, the Microbiome
- 28 Regression-Based Kernel Association Test. AM J HUM GENET 96, 797-807 (2015).
- 29 13. Shi, P., Zhang, A. & Li, H. Regression Analysis for Microbiome Compositional Data. ANN APPL
- 30 STAT **10**(2016).

- 1 14. Lucas, S., et al.. Short-chain fatty acids regulate systemic bone mass and protect from
- 2 pathological bone loss. NAT COMMUN 9, 55 (2018).
- 3 15. LeBlanc, J.G., et al.. Beneficial effects on host energy metabolism of short-chain fatty acids and
- 4 vitamins produced by commensal and probiotic bacteria. MICROB CELL FACT 16, 79 (2017).
- 5 16. Schepper, J.D., et al.. Probiotics in Gut-Bone Signaling. ADV EXP MED BIOL 1033, 225-247
- 6 (2017).
- 7 17. Collins, F.L., Rios-Arce, N.D., Schepper, J.D., Parameswaran, N. & McCabe, L.R. The Potential
- 8 of Probiotics as a Therapy for Osteoporosis. *Microbiol Spectr* **5**(2017).
- 9 18. Grover, S., Del, G.M.F., Stein, C.M. & Ziegler, A. Mendelian Randomization. Methods Mol Biol
- 10 1666, 581-628 (2017).
- 11 19. Kurt, R. & Smolen, J.S. Inflammatory bone loss: pathogenesis and therapeutic intervention. NAT
- 12 REV DRUG DISCOV 11, 234-250 (2012).
- 13 20. Giridharan, S. & Srinivasan, M. Mechanisms of NF-kappaB p65 and strategies for therapeutic
- 14 manipulation. J Inflamm Res 11, 407-419 (2018).
- 15 21. Couper, K.N., Blount, D.G. & Riley, E.M. IL-10: the master regulator of immunity to infection. J
- 16 IMMUNOL 180, 5771-5777 (2008).
- 17 22. Chang, J., et al.. Inhibition of Osteoblast Functions by IKK/NF- K B in Osteoporosis. NAT MED
- 18 **15**, 682-689 (2009).
- 19 23. Nobel, Y.R., et al.. Metabolic and metagenomic outcomes from early-life pulsed antibiotic
- 20 treatment. NAT COMMUN 6, 7486 (2015).
- 21 24. Larsen, O.F.A. & Claassen, E. The mechanistic link between health and gut microbiota diversity.
- 22 Sci Rep 8(2018).
- 23 25. Sprent, P. Sign Test, (2011).
- 24 26. Koller, D.L., et al.. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs
- 25 associated with bone mineral density in premenopausal women. J BONE MINER RES 28, 547-558
- 26 (2013).
- 27 27. Cuív, P.Ó., et al.. The gut bacterium and pathobiont Bacteroides vulgatus activates NF- K B in a
- 28 human gut epithelial cell line in a strain and growth phase dependent manner. ANAEROBE 47, 209-217
- 29 (2017).
- 30 28. Yamaguchi, M., Vikulina, T., Arbiser, J.L. & Weitzmann, M.N. Suppression of NF-kappaB

- perpetuity.
  It is made available under a CC-BY-NC-ND 4.0 International license .
- 1 activation by gentian violet promotes osteoblastogenesis and suppresses osteoclastogenesis. CURR
- 2 *MOL MED* **14**, 783-792 (2014).
- 3 29. Bhanu Chandra, M., Salmaan, K., Alex, L. & Wei-Shou, H. Glucose metabolism in mammalian
- 4 cell culture: new insights for tweaking vintage pathways. TRENDS BIOTECHNOL 28, 476-484 (2010).
- 5 30. Boffi, F.M., et al.. Effects of chemical ischemia on purine nucleotides, free radical generation,
- 6 lipids peroxidation and intracellular calcium levels in C2C12 myotube derived from mouse myocytes. J
- 7 *VET MED SCI* **64**, 483 (2002).
- 8 31. Moriarty, D.J.W. Measurement of Bacterial Growth Rates in Aquatic Systems from Rates of
- 9 Nucleic Acid Synthesis, (1986).
- 10 32. Rooks, M.G. & Garrett, W.S. Gut microbiota, metabolites and host immunity. NAT REV
- 11 *IMMUNOL* **16**, 341-352 (2016).
- 12 33. Yan, J., et al.. Gut microbiota induce IGF-1 and promote bone formation and growth. Proc Natl
- 13 *Acad Sci U S A* **113**, E7554-E7563 (2016).
- 14 34. Park, J.S., Lee, E.J., Lee, J.C., Kim, W.K. & Kim, H.S. Anti-inflammatory effects of short chain
- 15 fatty acids in IFN- γ -stimulated RAW 264.7 murine macrophage cells: Involvement of NF- κ B and
- 16 ERK signaling pathways. INT IMMUNOPHARMACOL 7, 70-77 (2007).
- 17 35. Heyen, J.R., Ye, S., Finck, B.N. & Johnson, R.W. Interleukin (IL)-10 inhibits IL-6 production in
- 18 microglia by preventing activation of NF-kappaB. Brain Res Mol Brain Res 77, 138-147 (2000).
- 19 36. Yuille, S., Reichardt, N. & Panda, S. Human gut bacteria as potent class I histone deacetylase
- inhibitors in vitro through production of butyric acid and valeric acid. PLOS ONE 13, e201073 (2018).
- 21 37. Li, Y., et al.. Gut commensal derived-valeric acid protects against radiation injuries. Gut
- 22 Microbes, 1-18 (2020).
- 23 38. Sandra, M. & Macfarlane, G.T. Regulation of short-chain fatty acid production. P NUTR SOC 62,
- 24 67-72 (2003).
- 25 39. Coyte, K.Z. & Rakoff-Nahoum, S. Understanding Competition and Cooperation within the
- 26 Mammalian Gut Microbiome. CURR BIOL 29, R538-R544 (2019).
- 27 40. Buchfink, B., Xie, C. & Huson, D.H. Fast and sensitive protein alignment using DIAMOND. NAT
- 28 *METHODS* **12**, 59-60 (2015).
- 41. Huson, D., Auch, A.J. & Schuster, S. MEGAN analysis of metagenomic data. GENOME RES 17,
- 30 377-386 (2007).

- 1 42. Jain, M., et al.. The importance of rare species: a trait-based assessment of rare species
- 2 contributions to functional diversity and possible ecosystem function in tall-grass prairies. ECOL
- 3 EVOL 4, 104-112 (2014).
- 4 43. Piercy, K.L. & Troiano, R.P. Physical Activity Guidelines for Americans From the US
- 5 Department of Health and Human Services. Circ Cardiovasc Qual Outcomes 11, e5263 (2018).
- 6 44. Du, Y., Zhao, L.J., Xu, Q., Wu, K.H. & Deng, H.W. Socioeconomic status and bone mineral
- 7 density in adults by race/ethnicity and gender: the Louisiana osteoporosis study. Osteoporos Int 28,
- 8 1699-1709 (2017).
- 9 45. Zhou, S., et al.. Age-dependent variations of cancellous bone in response to ovariectomy in
- 10 C57BL/6J mice. EXP THER MED 15, 3623-3632 (2018).
- 11 46. Magnus, M.C et al. Vitamin D and risk of pregnancy related hypertensive disorders: mendelian
- 12 randomisation study. BMJ 361, - (2018).
- 13 47. Sanna, S., et al.. Causal relationships among the gut microbiome, short-chain fatty acids and
- 14 metabolic diseases. NAT GENET 51, 600-605 (2019).
- 15 48. Sudmant, P.H., et al.. An integrated map of structural variation in 2,504 human genomes.
- 16 NATURE 526, 75-81 (2015).
- 17 49. Bowden, J., Davey, S.G., Haycock, P.C. & Burgess, S. Consistent Estimation in Mendelian
- 18 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. GENET
- 19 EPIDEMIOL 40, 304-314 (2016).
- 20 50. Schmittgen, T.D. & Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method.
- 21 NAT PROTOC 3, 1101-1108 (2008).

## Acknowledgement

1

13

14

- 2 HW Deng and H Shen were partially supported by grants from the National Institutes
- 3 of Health [U19AG05537301, R01AR069055, P20GM109036, R01MH104680,
- 4 R01AG061917], and the Edward G. Schlieder Endowment and the Drs. W. C. Tsai
- 5 and P. T. Kung Professorship from Tulane University. J Shen was partially supported
- 6 by grants from the Science and Technology Program of Guangzhou, China
- 7 [201604020007], and the National Natural Science Foundation of China [81770878].
- 8 HM Xiao was partially supported by the National Key R&D Program of China
- 9 (2016YFC1201805 and 2017YFC1001100).
- We thank Feng-Zhu Sun, Guo-Zhen Wang, Jun Wang, Wei-Chang Huang, Zun Wang,
- Yong Liu, Lin-Dong Jiang, Rui-Ke Liu, Zhi-Mei Feng, Yuan-Yuan Hu, Lin-Ping Peng
- and Chun-Ping Zeng for their suggestions and supports for this study.

## **Author contributions**

- 15 HWD conceived, designed, initiated and directed the whole project. JG, QZ, KJS,
- 16 XHM, FYL, and CLG contributed to the data analysis. JS and HMX managed the
- study done in their institutions. DYP, ZC, and ZFL performed clinical diagnosis and
- recruited subjects. CP, XJX, YCC, RZ, XFW, ZXA, JML, YQS, and YHZ collected
- samples and clinical phenotypes. SJY conducted animal experiments. XL drafted the
- 20 manuscript. HWD revised, rewrote/re-structured some sections and finalized the
- 21 manuscript. NJY, QZ, BYG, HML, WQL, CJP, XMS and HS contributed to text
- 22 revision and/or discussion.

## **Author information**

1

2

- 3 The authors declare no competing financial interests.
- Correspondence and requests for materials should be addressed to Hong-Wen Deng 4
- Shen (shenjiedr@163.com) 5 (hdeng2@tulane.edu), Jie and Hong-Mei
- 6 (hmxiao@csu.edu.cn).
- The data that support the findings of this study are available from the corresponding 7
- author upon request and approval of the team and respective institutions. 8

# Table 1. Characteristics of the Chinese study cohort

Phenotypes	Max	Min	Mean	Standard Deviation
Age (years)	64.59	41.47	52.85	2.92
BMI (kg/m²)	33.73	16.42	22.97	2.87
YSM (years)	8.99	0.06	1.96	0.94
FSH (mIU/mL)	208.20	1.08	76.24	32.63
L1-L4 BMD (g/cm <sup>2</sup> )	1.85	0.69	1.05	0.16
HTOT BMD (g/cm <sup>2</sup> )	1.36	0.61	0.93	0.12
FN BMD (g/cm <sup>2</sup> )	1.26	0.58	0.86	0.12
UD-RU BMD (g/cm <sup>2</sup> )	0.61	0.22	0.40	0.06

## 2 Abbreviations:

6

- 3 YSM years since menopause; FSH follicle stimulating hormone; BMI body mass
- 4 index; BMD bone mineral density; L1-L4 lumbar spine; HTOT left total hip; FN
- 5 femoral neck; UD-RU ultra-distal radius and ulna.

## Table 2. Correlation between GM functional capacity and BMD variation

Module ID	γ	<i>p</i> -value	<i>Q</i> -value	Module names	Phenotypes
M00002	-0.122	0.007	0.234	Glycolysis	L1-L4 BMD
M00048	-0.119	0.008	0.234	IMP biosynthesis	L1-L4 BMD
M00855	-0.119	0.008	0.234	Glycogen degradation	L1-L4 BMD
M00002	-0.118	0.009	0.153	Glycolysis	UD-RU BMD
M00003	-0.119	0.008	0.153	Gluconeogenesis	UD-RU BMD
M00050	-0.143	0.002	0.079	GTP biosynthesis	UD-RU BMD
M00727	-0.135	0.003	0.079	CAMP resistance	UD-RU BMD

#### Note: 2

1


- γ coefficient of the partial Spearman correlation between GM functional module and 3
- phenotype; p-value p-value of the coefficient in partial Spearman correlation 4
- analysis; O-value p-value adjusted by false discovery rate; Glycolysis -5
- biosynthesis module involving three-carbon compounds; **IMP** 6
- 7 - PRPP + glutamine → IMP; Glycogen degradation - glycogen → glucose-6P;
- Gluconeogenesis oxaloacetate → fructose-6P; GTP biosynthesis IMP → GDP, 8
- GTP; CAMP resistance N-acetylmuramoyl-L-alanine amidase AmiA and AmiC. We 9
- only tested the modules whose relative abundance > 0.10%. 10


#### Abbreviations: 11

- GM gut microbiota; BMD bone mineral density; L1-L4 lumbar spine; UD-RU -12
- ultra-distal radius and ulna; PRPP phosphoribosylpyrophosphate; IMP inosine 13
- monophosphate; GDP guanosine 5'-diphosphate; GTP guanosine 5'-triphosphate; 14
- CAMP cationic antimicrobial peptide. 15

- Figure legends 1
- Figure 1. Unigene accumulation curve, bacterial species composition and 2
- correlation 3


Figure 1






(a) Unigene accumulation curve: the number of unigenes (y-axis) was plotted against the number of samples (x-axis). (b) Bacterial species composition in the study cohort composed of rare and non-rare bacterial species. Different colours represent different bacterial species. Numbers in parentheses indicate the proportion of each bacterial species. "Rare species" include all those bacterial species with relative abundances less than 0.10%. (c) Heatmap of co-occurrence between the relative abundances of non-rare species. Numbers in the plot represent Spearman correlation coefficients of pairwise two bacterial species.

Figure 2. Bacteroides vulgatus regulates bone remodeling in mice in vivo



Changes in various bone-associated phenotypes in mice gavaged with *B. vulgatus* or normal saline (NS) for 8 weeks (performed at age of 8 weeks after ovariectomy): (a) bone mineral density (BMD) of the 5<sup>th</sup> lumbar vertebral body; (b) serum osteocalcin (OC) concentrations; (c) serum C-telopeptide of type I collagen (CTX-I) concentrations; (d) representative histomorphology of the 5<sup>th</sup> lumbar vertebral body using hematoxylin-eosin staining. Red arrows point to trabecular bone; (e) representative micro-computed tomograph images of the 5<sup>th</sup> lumbar vertebral body by three-dimensional reconstructions. (Note: in A, B, and C, n = 18, and \* indicates p-value < 0.05.)

Figure 3. Valeric acid influences osteoclast and osteoblast differentiation in vitro



Effects of valeric acid (VA) on osteoclast differentiation of RAW264.7 cells (induced 1 by receptor activator of nuclear factor-κB ligand [RANKL]) and osteoblast 2 differentiation of MC3T3-E1 cells: (a) Microscopic images of tartrate-resistant acid 3 phosphatase staining of osteoclast-like cells induced from RAW264.7 cells after 5 4 days of osteoclastogenesis with/without VA treatment. Red arrows indicate 5 osteoclast-like cells. (b) Alkaline phosphatase (ALP) staining for osteoblast 6 differentiation and alizarin red S (AR-S) staining for extracellular matrix 7 8 mineralization by MC3T3-E1 cells after 14 days of osteoblastogenesis with/without VA treatment; (c) Western blot of NF-κB p65 protein in osteoclast-like cells 9 with/without VA treatment; (d) Western blot of NF-kB p65 protein in osteoblasts 10 with/without VA treatment; the "induce" means the MC3T3-E1 cells were induced 11 12 into osteoblasts by osteoblastogenic medium without VA; (e) IL-10 mRNA expression in osteoclast-like cells with/without VA; (f) IL-10 mRNA expression in osteoblasts 13 with/without VA. \* indicates p-value < 0.05, and \*\* means p-value < 0.01. 14